Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women

Horacio B. Croxatto, Ana M. Salvatierra, Blanca Fuentealba, Rebeca Massai

Resultado de la investigación: Contribución a una revistaArtículo

22 Citas (Scopus)

Resumen

The effectiveness of a sequential regimen consisting of mifepristone, 10 mg/day for 15 days, followed by nomegestrol acetate (NOMA), 5 mg/day for the next 13 days, for inhibiting ovulation and maintaining regular bleeding cycles was assessed in 10 surgically sterilized volunteers who were followed for one pretreatment and three treated cycles. Hormonal determinations in blood and urine, ovarian ultrasonography, bleeding records in all cycles and an endometrial biopsy taken on day 22-25 of the third treatment cycle were used to monitor the effects of treatment. During treatment, 24 monophasic (no sustained progesterone rise above 12 nmol/l) and six biphasic cycles were recorded. Nine follicular ruptures were detected echographically in these 30 treated cycles, five of which occurred in monophasic cycles. All follicular ruptures occurred on days 1-7 of NOMA treatment. Echographic and endocrine features of ovulatory cycles were both present in only four treated cycles (13.3%). Development of a secretory endometrium was achieved in all cases, but it was always irregular. Regular withdrawal bleeding occurred in all subjects and no adverse reactions were recorded. The ovarian and endometrial effects of this regimen justify testing its contraceptive effectiveness in phase 2 clinical trials.

Idioma originalInglés
Páginas (desde-hasta)3297-3302
Número de páginas6
PublicaciónHuman Reproduction
Volumen13
N.º12
DOI
EstadoPublicada - 1998

Áreas temáticas de ASJC Scopus

  • Biología del desarrollo
  • Fisiología
  • Ginecología y obstetricia
  • Medicina reproductiva
  • Rehabilitación

Huella Profundice en los temas de investigación de 'Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women'. En conjunto forman una huella única.

  • Citar esto